FLAG Therapeutics Announces the Granting of Orphan Drug Designation to FLAG-003 in Both the US and EU for the Treatment of Glioma
FLAG Therapeutics Inc. announced today that the U.S. Food and Drug Administration’s Office of Orphan Products Development and the European Medicines Agency (EMA) have both granted Orphan Drug Designation to FLAG-003 for the treatment of glioma. Gliomas (including Glioblastoma) are the most... - March 02, 2016
FLAG Therapeutics Awarded a North Carolina Biotechnology Center Small Business Research Loan to Advance Its Lead Oncology Drug
FLAG Therapeutics Inc., a company focused on novel, bispecific oncology drugs, has received a $250,000 Small Business Research Loan (SRL) from the North Carolina Biotechnology Center. This capital will enable FLAG to pursue significant preclinical milestones to advance its lead bispecific... - March 27, 2015
Press Releases 1 - 2 of 2